Corticotropin (ACTH) and melanotropin (MSH) peptides (melanocortins) are produced not only in the pituitary but also in the brain, with highest concentrations in the arcuate nudeus of the hypothalamus and the commisural nucleus of the solitary tract. We have identified a receptor for MSH and ACTH peptides that is specdflcally expressed in regions of the hypothalamus and limbic system. This melanocortin receptor (MC3-R) is found in neurons of the arcuate nucleus known to express proopiomelanocortin (POMC) and in a subset of the nuclei to which these neurons send projections.The MC3-R is 43% identical to the MSH receptor present in melanocytes and is strongly coupled to adenylyl cyclase. Unlike the MSH or ACTH receptors, MC3-R is potendy activated by 'yMSH peptides, POMC products that were named for their amino acid homology with a-and f-MSH, but lack melanotropic activity. The primary biological role of the yMSH peptides is not yet understood. The location and properties of this receptor provide a pharmacological basis for the action of POMC peptides produced in the brain and possibly a specific physiological role for -MSH.The large proopiomelanocortin (POMC) protein is processed into three main families ofpeptides with adrenocorticotropic, melanotropic, or opiate activities. The melanocortins, which include all POMC peptides except (3-endorphin, are primarily known for their role in the regulation of adrenal steroid production [corticotropin (ACTH)] and pigmentation [a melanotropin (a-MSH)]. In addition to these well-known effects, administration of melanocortin peptides has been reported to increase retention of learned behaviors (1, 2), induce grooming behavior (3), decrease fever (4, 5), stimulate nerve regeneration (6, 7), and increase heart rate, blood pressure, and natriuresis (8, 9). Many ofthese biological activities have been demonstrated to result from direct action of the melanocortin peptides in the brain.Recently, the cloning of the MSH (10, 11) and ACTH receptors (10) (MSH-R and ACTH-R) has provided probes for the examination of MSH-R and ACTH-R mRNA expression. Thus far, MSH-R and ACTH-R mRNA expression has only been detected in melanocytes and in the adrenal cortex, respectively. Although specific high-affinity MSH and ACTH binding has been reported in brain, with highest levels in the hypothalamus (12, 13), no MSH-R or ACTH-R mRNA was detected in the brain by either Northern hybridization or in situ hybridization (14,15). Additionally, melanocortin binding and biological action in the brain display pharmacological profiles that do not match those of either the adrenal The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.ACTH-R or the melanocyte MSH-R. These data suggested the existence of unique melanocortin receptor(s) expressed specifically in the brain.We report here the cloning and characterization of a neural-specific melanocorti...

D-fenfluramine (d-FEN) was once widely prescribed and was among the most effective weight loss drugs, but was withdrawn from clinical use because of reports of cardiac complications in a subset of patients. Discerning the neurobiology underlying the anorexic action of d-FEN may facilitate the development of new drugs to prevent and treat obesity. Through a combination of functional neuroanatomy, feeding, and electrophysiology studies in rodents, we show that d-FEN-induced anorexia requires activation of central nervous system melanocortin pathways. These results provide a mechanistic explanation of d-FEN's anorexic actions and indicate that drugs targeting these downstream melanocortin pathways may prove to be effective and more selective anti-obesity treatments.

No abstract

The hypothalamic arcuate nucleus has an essential role in mediating the homeostatic responses of the thyroid axis to fasting by altering the sensitivity of prothyrotropin-releasing hormone (pro-TRH) gene expression in the paraventricular nucleus (PVN) to feedback regulation by thyroid hormone. Because agouti-related protein (AGRP), a leptin-regulated, arcuate nucleus-derived peptide with ␣-MSH antagonist activity, is contained in axon terminals that terminate on TRH neurons in the PVN, we raised the possibility that ␣-MSH may also participate in the mechanism by which leptin influences pro-TRH gene expression. By double-labeling immunocytochemistry, ␣-MSH-IR axon varicosities were juxtaposed to ϳ70% of pro-TRH neurons in the anterior and periventricular parvocellular subdivisions of the PVN and to 34% of pro-TRH neurons in the medial parvocellular subdivision, establishing synaptic contacts both on the cell soma and dendrites. All pro-TRH neurons receiving contacts by ␣-MSH-containing fibers also were innervated by axons containing AGRP. The intracerebroventricular infusion of 300 ng of ␣-MSH every 6 hr for 3 d prevented fasting-induced suppression of pro-TRH in the PVN but had no effect on AGRP mRNA in the arcuate nucleus. ␣-MSH also increased circulating levels of free thyroxine (T4) 2.5-fold over the levels in fasted controls, but free T4 did not reach the levels in fed controls. These data suggest that ␣-MSH has an important role in the activation of pro-TRH gene expression in hypophysiotropic neurons via either a mono-and/or multisynaptic pathway to the PVN, but factors in addition to ␣-MSH also contribute to the mechanism by which leptin administration restores thyroid hormone levels to normal in fasted animals.